[go: up one dir, main page]

NO20035121L - New use - Google Patents

New use

Info

Publication number
NO20035121L
NO20035121L NO20035121A NO20035121A NO20035121L NO 20035121 L NO20035121 L NO 20035121L NO 20035121 A NO20035121 A NO 20035121A NO 20035121 A NO20035121 A NO 20035121A NO 20035121 L NO20035121 L NO 20035121L
Authority
NO
Norway
Prior art keywords
functional
conditions
visceral pain
pain
bowel function
Prior art date
Application number
NO20035121A
Other languages
Norwegian (no)
Other versions
NO20035121D0 (en
Inventor
Douglas William Pierre Hay
Gareth John Sanger
Yadataka Yamada
Original Assignee
Smithkline Beecham Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0112208A external-priority patent/GB0112208D0/en
Priority claimed from GB0129268A external-priority patent/GB0129268D0/en
Application filed by Smithkline Beecham Co filed Critical Smithkline Beecham Co
Publication of NO20035121D0 publication Critical patent/NO20035121D0/en
Publication of NO20035121L publication Critical patent/NO20035121L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nutrition Science (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Fremgangsmåte for behandling og/eller profylakse av tilstander kjennetegnet ved forandret tarmfunksjon og/eller visceral smerte hos mennesker eller ikke-humane pattedyr, hvilken fremgangsmåte innbefatter administrasjon av en effektiv, ikke-toksisk og farmasøytisk akseptabel mengde av en NK-reseptorantagonist, hvori tilstanden kjennetegnes ved forandret tarmfunksjon og/eller visceral smerte er utvalgt fra visse irritable tannsyndromtilstander, funksjonell abdominal oppblåsthet, funksjonell konstipasjon, funksjonell diarré, andre tarmtilstander og funksjonell abdominal smerte.A method of treating and / or prophylaxis of conditions characterized by altered bowel function and / or visceral pain in humans or non-human mammals, which method comprises administering an effective, non-toxic and pharmaceutically acceptable amount of an NK receptor antagonist, wherein the condition is characterized in altered bowel function and / or visceral pain are selected from certain irritable dental syndrome conditions, functional abdominal bloating, functional constipation, functional diarrhea, other bowel conditions and functional abdominal pain.

NO20035121A 2001-05-18 2003-11-17 New use NO20035121L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0112208A GB0112208D0 (en) 2001-05-18 2001-05-18 New use
GB0129268A GB0129268D0 (en) 2001-12-06 2001-12-06 Novel use
PCT/US2002/015911 WO2002094187A2 (en) 2001-05-18 2002-05-17 Novel use

Publications (2)

Publication Number Publication Date
NO20035121D0 NO20035121D0 (en) 2003-11-17
NO20035121L true NO20035121L (en) 2003-11-17

Family

ID=26246093

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20035121A NO20035121L (en) 2001-05-18 2003-11-17 New use

Country Status (19)

Country Link
EP (1) EP1387687A4 (en)
JP (1) JP2004534761A (en)
KR (1) KR20040016865A (en)
CN (1) CN1269483C (en)
AR (1) AR045879A1 (en)
AU (1) AU2002303811B2 (en)
BR (1) BR0209662A (en)
CA (1) CA2447063A1 (en)
CZ (1) CZ20033115A3 (en)
HU (1) HUP0400966A2 (en)
IL (1) IL158701A0 (en)
MX (1) MXPA03010509A (en)
MY (1) MY134211A (en)
NO (1) NO20035121L (en)
NZ (1) NZ529462A (en)
PE (1) PE20021067A1 (en)
PL (1) PL367308A1 (en)
TW (1) TWI243678B (en)
WO (1) WO2002094187A2 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
ATE477268T1 (en) 2003-01-28 2010-08-15 Ironwood Pharmaceuticals Inc COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS
TW200602055A (en) * 2004-03-30 2006-01-16 Smithkline Beecham Corp Spray dried pharmaceutical compositions
WO2005100997A2 (en) * 2004-04-16 2005-10-27 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with tachykinin receptor 3 (tacr3)
AR058676A1 (en) * 2005-09-30 2008-02-20 Smithkline Beecham Corp PHARMACEUTICAL COMPOSITION CONTAINING (S) - (-) - N- (ALFA- ETILBENCIL) -3- HYDROXY- 2- PHENYLKINOLINE-4-CARBOXAMIDE (TALNETANT), POVIDONA, MANITOL AND TENSIOACTIVE, PROCEDURE TO PREPARE IT AND DOSAGE FORM UNDERSTANDS
TW201018662A (en) 2005-12-12 2010-05-16 Astrazeneca Ab Alkylsulphonamide quinolines
JP5546451B2 (en) 2007-06-04 2014-07-09 シナジー ファーマシューティカルズ インコーポレイテッド Agonyl cyclase agonists useful in the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US20100120694A1 (en) 2008-06-04 2010-05-13 Synergy Pharmaceuticals, Inc. Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
EP3241839B1 (en) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
JP5502106B2 (en) 2008-12-31 2014-05-28 アーデリクス，インコーポレーテッド Compositions and methods for inhibiting NHE-mediated antiports in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal disorders
KR200452372Y1 (en) * 2010-05-14 2011-02-22 서일수 Communication line support device of construction lift
KR101034774B1 (en) * 2010-07-30 2011-05-17 (주)챔피온코리아 Lift device using wire rope
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
KR102138390B1 (en) 2012-08-21 2020-07-27 알데릭스, 인코포레이티드 Compounds and methods for inhibiting nhe-mediaded antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
HK1220696A1 (en) 2013-03-15 2017-05-12 Bausch Health Ireland Limited Agonists of guanylate cyclase and their uses
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
KR102287207B1 (en) 2013-04-12 2021-08-09 알데릭스, 인코포레이티드 Nhe3-binding compounds and methods for inhibiting phosphate transport
AU2014255512A1 (en) 2013-04-19 2015-11-12 Astrazeneca Ab A NK3 receptor antagonist compound (NK3RA) for use in a method for the treatment of polycystic ovary syndrome (PCOS)
EP4424697A3 (en) 2013-06-05 2024-12-25 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase c, method of making and using same
UA126283C2 (en) 2017-01-09 2022-09-14 Арделікс, Інк. COMPOUNDS USEFUL FOR THE TREATMENT OF DISORDERS OF THE GASTROINTESTINAL TRACT
CA3049679A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Inhibitors of nhe-mediated antiport

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2719311B1 (en) * 1994-03-18 1998-06-26 Sanofi Sa Compounds that are selective antagonists of the human NK3 receptor and their use as drugs and diagnostic tools.
US5434158A (en) * 1994-04-26 1995-07-18 Merck & Co., Inc. Spiro-substituted azacycles as neurokinin-3 antagonists
AR004735A1 (en) * 1995-11-24 1999-03-10 Smithkline Beecham Spa CHINOLEIN 4-AMIDO SUBSTITUTED, A PROCEDURE FOR ITS PREPARATION, A PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM AND THE USE OF THE SAME FOR THE PREPARATION OF A MEDICINAL PRODUCT.
AU8209898A (en) * 1997-05-23 1998-12-11 Smithkline Beecham Spa Quinoline-4-carboxamide derivatives as nk-2 and nk-3 receptor antagonists
CA2351865A1 (en) * 1998-11-20 2000-06-02 Smithkline Beecham S.P.A. Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists

Also Published As

Publication number Publication date
CN1509175A (en) 2004-06-30
IL158701A0 (en) 2004-05-12
EP1387687A2 (en) 2004-02-11
CZ20033115A3 (en) 2004-09-15
BR0209662A (en) 2004-04-20
PL367308A1 (en) 2005-02-21
TWI243678B (en) 2005-11-21
MY134211A (en) 2007-11-30
AU2002303811B2 (en) 2005-07-07
PE20021067A1 (en) 2003-02-02
EP1387687A4 (en) 2006-07-05
NO20035121D0 (en) 2003-11-17
HUP0400966A2 (en) 2004-08-30
CN1269483C (en) 2006-08-16
WO2002094187A2 (en) 2002-11-28
CA2447063A1 (en) 2002-11-28
JP2004534761A (en) 2004-11-18
WO2002094187A3 (en) 2003-05-30
NZ529462A (en) 2005-07-29
KR20040016865A (en) 2004-02-25
AR045879A1 (en) 2005-11-16
MXPA03010509A (en) 2004-03-02

Similar Documents

Publication Publication Date Title
NO20035121L (en) New use
US4786639A (en) Method for the treatment of reversible airways obstruction and asthma
HUS1700052I1 (en) Compositions for affecting weight loss comprising an opioid antagonist and bupropion
WO2005000807A3 (en) Benzodiazepine cgrp receptor antagonists
NO985977L (en) Spiro-piperidine derivatives and their use as therapeutic agents
NO20020792L (en) Treatment of restless leg syndrome with a combination of clonidine and opioid
WO2002038142A3 (en) Serotonergic compositions and methods for treatment of mild cognitive impairment
DK0782445T3 (en) Combination of an opioid antagonist and a selective serotonin reuptake inhibitor to treat alcoholism and alcohol dependence
DE60107835D1 (en) MEDICAL COMPOSITIONS FOR PROMOTING THE ACTIVATION OF THE DIGES
IL149378A0 (en) Composition for treatment of constipation and irritable bowel syndrome
TW200505903A (en) CGRP receptor antagonists
BR0010061A (en) Treatment of il-13 antagonist fibrosis and il-13 receptor chains
EP1641423A4 (en) CGRP RECEPTOR ANTAGONISTS
WO2004091514A3 (en) Cgrp receptor antagonists
AU2002360592A8 (en) Inhibitors of hepatitis c virus
WO2001041748A3 (en) Pharmaceutical combinations and their use in treating gastrointestinal disorders
MY133503A (en) Selective iglur5 receptor antagonists for the treatment of migrane
WO1999047131A3 (en) Combination of a gaba-a alpha 5 inverse agonist and an acetylcholinesterase inhibitor
WO2001035950A3 (en) Benzamide therapeutics and methods for treating inflammatory bowel disease
WO2005072308A3 (en) Cgrp receptor antagonists
TN2009000253A1 (en) Solid dispersion of a neurokinin antagonist
WO2002064125A3 (en) Use of a farnesoid x receptor antagonist for treating hyperlipidemia
EP1146873A4 (en) Anti-androgens and methods for treating disease
DE69626321D1 (en) SUBSTITUTED 4- (1H-BENZIMIDAZOL-2-YL-AMINO) PIPERIDINE FOR THE TREATMENT OF ALLERGIC DISEASES
NO20003694L (en) VLA-4 antagonists

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application